Sucrose acetate isobutyrate (SAIB) and glyceryl monooleate (GMO) hybrid nanoparticles for bioavailability enhancement of rivaroxaban: an optimization study.

Al-Shoubki, Adam A; Teaima, Mahmoud H; Abdelmonem, Rehab; El-Nabarawi, Mohamed A; Elhabal, Sammar Fathy

Al-Shoubki, Adam A; Teaima, Mahmoud H; Abdelmonem, Rehab; El-Nabarawi, Mohamed A; Elhabal, Sammar Fathy.

Afiliação

Al-Shoubki AA; Department of Pharmaceutics and Industrial Pharmacy, University of Derna, Derna, Libya.
Teaima MH; Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.
Abdelmonem R; Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.
El-Nabarawi MA; Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MuST), Giza, Egypt.
Elhabal SF; Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.

Pharm Dev Technol ; 28(10): 928-938, 2023 Dec.

Article em En | MEDLINE | ID: mdl-37870222

Assuntos

Nanopartículas; Rivaroxabana; Plantas Geneticamente Modificadas; Disponibilidade Biológica; Sacarose

Palavras-chave

Nanonization; bioavailability enhancement; glyceryl monooleate; rivaroxaban; sucrose acetate isobutyrate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Rivaroxabana Idioma: En Revista: Pharm Dev Technol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google